BioXcel Therapeutics Announces BXCL501 Program Initiative for Prevention and Treatment of Acute Agitation using Wearable Digital Devices Sep 18, 2019
BioXcel Therapeutics Receives FDA Orphan Drug Designation for BXCL701 for the Treatment of Acute Myeloid Leukemia (AML) Sep 4, 2019
BioXcel Therapeutics Announces Award of Grant by U.S. Department of Defense’s (“DoD”) Congressionally Directed Medical Research Programs (“CDMRP”) for Development of BXCL501 Aug 20, 2019
BioXcel Therapeutics Reports Second Quarter 2019 Financial Results and Provides Business Update Aug 6, 2019
BioXcel Therapeutics to Report Second Quarter and Half Year 2019 Financial Results and Business Update Jul 30, 2019
BioXcel Therapeutics Announces BXCL501 Met Primary Endpoint in Phase 1b Placebo-Controlled Trial in the Treatment of Agitation in Patients with Schizophrenia Jul 22, 2019
BioXcel Therapeutics to Participate in the BMO 2019 Prescriptions for Success Healthcare Conference Jun 18, 2019
BioXcel Therapeutics Completes Dosing Two Cohorts of Agitated Schizophrenia Patients with BXCL501 in a Phase 2 Efficacy Trial Jun 10, 2019
